[
  {
    "objectID": "quarto/index.html",
    "href": "quarto/index.html",
    "title": "Impact of Body Mass Index on Mortality in Hospitalized Patients With Coronary Artery Disease",
    "section": "",
    "text": "Reference Paper: Sreenivasan et al. 2022\nStudy Objective: Examine the impact of body mass index (BMI) on outcomes among patients with coronary artery disease (CAD).\nData Source: Cross-sectional analysis of the National Inpatient Sample (NIS) from 2018 to 2020.\nPatient Selection: Included all hospitalized patients diagnosed with a principal diagnosis or a history of CAD.\nBMI Categories:\n\nUnderweight: BMI ≤19.9 kg/m²\nNormal Weight: BMI 20.0 to 24.9 kg/m²\nOverweight: BMI 25.0 to 29.9 kg/m²\nClass I Obesity: BMI 30.0 to 34.9 kg/m²\nClass II Obesity: BMI 35.0 to 39.9 kg/m²\nClass III Obesity: BMI ≥40.0 kg/m²\n\nPrimary Outcomes:\n\nIn-hospital all-cause mortality\nTotal hospital length of stay (days)\nTotal charge, inflation adjusted to 2020 ($)\n\nStatistical Analysis: Multiple logistic and linear regression to determine the independent association of BMI categories with in-hospital mortality and length of stay, respectively, adjusted for:\n\nDemographics: Age, gender, race\nMedical History: Previous coronary artery bypass graft, myocardial infarction, percutaneous coronary intervention\nComorbidities: Charlson comorbidity index, atrial fibrillation, cerebrovascular disease, heart failure, peripheral vascular disease, dementia, tobacco use disorder, chronic obstructive pulmonary disease, valvular heart disease, liver disease, diabetes mellitus, hypertension, chronic kidney disease, dialysis dependence, anemia, hyperlipidemia, and any cancer.\n\nSoftware: All analyses were performed using R Version 4.4.1 (R Foundation for Statistical Computing, Vienna, Austria)"
  },
  {
    "objectID": "quarto/index.html#preamble",
    "href": "quarto/index.html#preamble",
    "title": "Impact of Body Mass Index on Mortality in Hospitalized Patients With Coronary Artery Disease",
    "section": "",
    "text": "Reference Paper: Sreenivasan et al. 2022\nStudy Objective: Examine the impact of body mass index (BMI) on outcomes among patients with coronary artery disease (CAD).\nData Source: Cross-sectional analysis of the National Inpatient Sample (NIS) from 2018 to 2020.\nPatient Selection: Included all hospitalized patients diagnosed with a principal diagnosis or a history of CAD.\nBMI Categories:\n\nUnderweight: BMI ≤19.9 kg/m²\nNormal Weight: BMI 20.0 to 24.9 kg/m²\nOverweight: BMI 25.0 to 29.9 kg/m²\nClass I Obesity: BMI 30.0 to 34.9 kg/m²\nClass II Obesity: BMI 35.0 to 39.9 kg/m²\nClass III Obesity: BMI ≥40.0 kg/m²\n\nPrimary Outcomes:\n\nIn-hospital all-cause mortality\nTotal hospital length of stay (days)\nTotal charge, inflation adjusted to 2020 ($)\n\nStatistical Analysis: Multiple logistic and linear regression to determine the independent association of BMI categories with in-hospital mortality and length of stay, respectively, adjusted for:\n\nDemographics: Age, gender, race\nMedical History: Previous coronary artery bypass graft, myocardial infarction, percutaneous coronary intervention\nComorbidities: Charlson comorbidity index, atrial fibrillation, cerebrovascular disease, heart failure, peripheral vascular disease, dementia, tobacco use disorder, chronic obstructive pulmonary disease, valvular heart disease, liver disease, diabetes mellitus, hypertension, chronic kidney disease, dialysis dependence, anemia, hyperlipidemia, and any cancer.\n\nSoftware: All analyses were performed using R Version 4.4.1 (R Foundation for Statistical Computing, Vienna, Austria)"
  },
  {
    "objectID": "quarto/index.html#baseline-table",
    "href": "quarto/index.html#baseline-table",
    "title": "Impact of Body Mass Index on Mortality in Hospitalized Patients With Coronary Artery Disease",
    "section": "Baseline Table:",
    "text": "Baseline Table:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall, N = 3,693,5701\nNormal weight (BMI 20.0-24.9kg/m²), N = 266,9001\nClass I obesity (BMI 30.0-34.9kg/m²), N = 871,7601\nClass II obesity (BMI 35.0-39.9kg/m²), N = 722,2901\nClass III obesity (BMI ≥40.0kg/m²), N = 1,085,3701\nOverweight (BMI 25.0-29.9kg/m²), N = 353,2351\nUnderweight (BMI ≤19.9kg/m²), N = 394,0151\np-value2\n\n\n\n\nAge, y\n69 (12)\n76 (11)\n69 (11)\n67 (11)\n64 (11)\n72 (11)\n76 (11)\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    Female\n1,616,920 (44)\n100,455 (38)\n319,875 (37)\n299,680 (41)\n570,945 (53)\n130,815 (37)\n195,150 (50)\n\n\n\n\n    Male\n2,076,460 (56)\n166,410 (62)\n551,840 (63)\n422,580 (59)\n514,395 (47)\n222,395 (63)\n198,840 (50)\n\n\n\n\nRace\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    White\n2,703,165 (75)\n191,600 (73)\n652,690 (76)\n537,210 (76)\n784,280 (74)\n254,345 (74)\n283,040 (73)\n\n\n\n\n    Asian or Pacific Islander\n52,325 (1.4)\n8,020 (3.1)\n10,655 (1.2)\n6,380 (0.9)\n6,865 (0.6)\n6,885 (2.0)\n13,520 (3.5)\n\n\n\n\n    Black\n500,665 (14)\n34,105 (13)\n99,630 (12)\n92,615 (13)\n174,955 (16)\n41,910 (12)\n57,450 (15)\n\n\n\n\n    Hispanic\n262,035 (7.3)\n19,275 (7.4)\n67,735 (7.9)\n52,575 (7.4)\n68,870 (6.5)\n32,155 (9.3)\n21,425 (5.5)\n\n\n\n\n    Native American\n19,185 (0.5)\n1,145 (0.4)\n4,435 (0.5)\n3,645 (0.5)\n6,710 (0.6)\n1,460 (0.4)\n1,790 (0.5)\n\n\n\n\n    Other\n76,070 (2.1)\n6,840 (2.6)\n18,110 (2.1)\n14,150 (2.0)\n19,080 (1.8)\n8,870 (2.6)\n9,020 (2.3)\n\n\n\n\nIncome quartile by ZIP\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    $1 - $51,999\n1,163,180 (32)\n79,355 (30)\n259,145 (30)\n222,545 (31)\n372,445 (35)\n106,120 (31)\n123,570 (32)\n\n\n\n\n    $52,000 - $65,999\n1,024,375 (28)\n69,490 (26)\n239,565 (28)\n205,785 (29)\n312,985 (29)\n94,275 (27)\n102,275 (26)\n\n\n\n\n    $66,000 - $87,999\n849,875 (23)\n61,125 (23)\n208,045 (24)\n169,480 (24)\n241,895 (23)\n82,280 (24)\n87,050 (22)\n\n\n\n\n    $88,000 or more\n602,210 (17)\n52,990 (20)\n152,800 (18)\n113,750 (16)\n142,615 (13)\n65,175 (19)\n74,880 (19)\n\n\n\n\nHealthcare payer\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    Medicaid\n322,300 (8.7)\n15,330 (5.7)\n66,045 (7.6)\n63,840 (8.8)\n128,200 (12)\n23,420 (6.6)\n25,465 (6.5)\n\n\n\n\n    Medicare\n2,581,230 (70)\n218,785 (82)\n597,280 (69)\n473,805 (66)\n699,840 (65)\n265,840 (75)\n325,680 (83)\n\n\n\n\n    No charge\n7,220 (0.2)\n280 (0.1)\n2,135 (0.2)\n1,450 (0.2)\n2,335 (0.2)\n600 (0.2)\n420 (0.1)\n\n\n\n\n    Other\n85,255 (2.3)\n5,425 (2.0)\n22,045 (2.5)\n18,220 (2.5)\n24,045 (2.2)\n8,345 (2.4)\n7,175 (1.8)\n\n\n\n\n    Private\n618,350 (17)\n23,935 (9.0)\n164,200 (19)\n146,770 (20)\n204,370 (19)\n48,475 (14)\n30,600 (7.8)\n\n\n\n\n    Self-pay\n76,355 (2.1)\n3,005 (1.1)\n19,430 (2.2)\n17,680 (2.4)\n25,520 (2.4)\n6,345 (1.8)\n4,375 (1.1)\n\n\n\n\nCharlson comorbidity index\n3.69 (2.24)\n3.95 (2.42)\n3.49 (2.23)\n3.56 (2.19)\n3.85 (2.15)\n3.73 (2.34)\n3.70 (2.31)\n&lt;0.001\n\n\nHypertension\n3,341,650 (90)\n227,520 (85)\n798,815 (92)\n668,475 (93)\n1,007,545 (93)\n317,140 (90)\n322,155 (82)\n&lt;0.001\n\n\nDiabetes mellitus\n2,087,065 (57)\n100,760 (38)\n498,745 (57)\n454,870 (63)\n747,095 (69)\n180,495 (51)\n105,100 (27)\n&lt;0.001\n\n\nChronic kidney disease\n1,354,770 (37)\n98,430 (37)\n303,335 (35)\n259,600 (36)\n437,720 (40)\n130,165 (37)\n125,520 (32)\n&lt;0.001\n\n\nDialysis dependence\n180,850 (4.9)\n16,535 (6.2)\n41,915 (4.8)\n33,245 (4.6)\n48,045 (4.4)\n20,300 (5.7)\n20,810 (5.3)\n&lt;0.001\n\n\nLiver disease\n221,320 (6.0)\n18,780 (7.0)\n48,250 (5.5)\n40,230 (5.6)\n67,560 (6.2)\n23,525 (6.7)\n22,975 (5.8)\n&lt;0.001\n\n\nCancer\n202,055 (5.5)\n30,490 (11)\n42,635 (4.9)\n29,105 (4.0)\n35,785 (3.3)\n26,745 (7.6)\n37,295 (9.5)\n&lt;0.001\n\n\nCOPD\n1,417,520 (38)\n91,560 (34)\n285,555 (33)\n259,890 (36)\n481,845 (44)\n112,700 (32)\n185,970 (47)\n&lt;0.001\n\n\nAnemia\n265,740 (7.2)\n27,730 (10)\n53,245 (6.1)\n42,205 (5.8)\n74,515 (6.9)\n27,620 (7.8)\n40,425 (10)\n&lt;0.001\n\n\nPeripheral vascular disease\n582,665 (16)\n53,525 (20)\n142,280 (16)\n104,280 (14)\n127,720 (12)\n64,225 (18)\n90,635 (23)\n&lt;0.001\n\n\nAtrial fibrillation\n1,017,110 (28)\n77,730 (29)\n231,395 (27)\n192,880 (27)\n308,780 (28)\n98,005 (28)\n108,320 (27)\n&lt;0.001\n\n\nPrior MI\n889,950 (24)\n62,565 (23)\n221,635 (25)\n179,715 (25)\n245,730 (23)\n85,960 (24)\n94,345 (24)\n&lt;0.001\n\n\nPrior PCI\n923,435 (25)\n62,875 (24)\n246,795 (28)\n198,025 (27)\n246,455 (23)\n93,250 (26)\n76,035 (19)\n&lt;0.001\n\n\nPrior CABG\n645,200 (17)\n58,195 (22)\n170,955 (20)\n131,650 (18)\n145,945 (13)\n75,365 (21)\n63,090 (16)\n&lt;0.001\n\n\nCerebrovascular disease\n348,870 (9.4)\n30,175 (11)\n88,345 (10)\n63,825 (8.8)\n81,805 (7.5)\n39,635 (11)\n45,085 (11)\n&lt;0.001\n\n\nDementia\n272,005 (7.4)\n51,075 (19)\n44,965 (5.2)\n26,905 (3.7)\n29,990 (2.8)\n37,600 (11)\n81,470 (21)\n&lt;0.001\n\n\nHeart failure\n1,915,090 (52)\n126,000 (47)\n406,695 (47)\n365,340 (51)\n664,980 (61)\n164,925 (47)\n187,150 (47)\n&lt;0.001\n\n\nTobbacco use disorder\n26,585 (0.7)\n1,645 (0.6)\n6,570 (0.8)\n5,400 (0.7)\n7,340 (0.7)\n2,560 (0.7)\n3,070 (0.8)\n&lt;0.001\n\n\nHyperlipidemia\n2,577,040 (70)\n161,330 (60)\n660,670 (76)\n537,115 (74)\n747,645 (69)\n253,555 (72)\n216,725 (55)\n&lt;0.001\n\n\n\n1 Mean (SD); n (%)\n\n\n2 Wilcoxon rank-sum test for complex survey samples; chi-squared test with Rao & Scott’s second-order correction"
  },
  {
    "objectID": "quarto/index.html#outcomes-table",
    "href": "quarto/index.html#outcomes-table",
    "title": "Impact of Body Mass Index on Mortality in Hospitalized Patients With Coronary Artery Disease",
    "section": "Outcomes Table:",
    "text": "Outcomes Table:\n\n\n\n\n\n\n\n\nCharacteristic\nOverall, N = 3,693,5701\nNormal weight (BMI 20.0-24.9kg/m²), N = 266,9001\nClass I obesity (BMI 30.0-34.9kg/m²), N = 871,7601\nClass II obesity (BMI 35.0-39.9kg/m²), N = 722,2901\nClass III obesity (BMI ≥40.0kg/m²), N = 1,085,3701\nOverweight (BMI 25.0-29.9kg/m²), N = 353,2351\nUnderweight (BMI ≤19.9kg/m²), N = 394,0151\np-value2\n\n\n\n\nDied during hospitalization\n108,960 (3.0%)\n13,855 (5.2%)\n16,395 (1.9%)\n13,240 (1.8%)\n27,475 (2.5%)\n11,190 (3.2%)\n26,805 (6.8%)\n&lt;0.001\n\n\nLength of stay (days)\n4.0 (2.0, 7.0)\n5.0 (3.0, 9.0)\n4.0 (2.0, 6.0)\n4.0 (2.0, 6.0)\n4.0 (2.0, 7.0)\n4.0 (2.0, 8.0)\n5.0 (3.0, 9.0)\n&lt;0.001\n\n\nInflation-adjusted total charge ($)\n49,814 (26,900, 95,686)\n49,340 (27,125, 93,565)\n52,773 (27,789, 102,334)\n50,213 (26,849, 95,516)\n47,440 (26,022, 90,658)\n53,730 (28,587, 105,184)\n47,178 (26,253, 88,784)\n&lt;0.001\n\n\n\n1 n (%); Median (IQR)\n\n\n2 chi-squared test with Rao & Scott’s second-order correction; Wilcoxon rank-sum test for complex survey samples"
  },
  {
    "objectID": "quarto/index.html#multivariable-logistic-regression",
    "href": "quarto/index.html#multivariable-logistic-regression",
    "title": "Impact of Body Mass Index on Mortality in Hospitalized Patients With Coronary Artery Disease",
    "section": "Multivariable Logistic Regression:",
    "text": "Multivariable Logistic Regression:\n\nAll-Cause Mortality:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR1\n95% CI1\np-value\n\n\n\n\nBody mass index (BMI)\n\n\n\n\n\n\n\n\n    Normal weight (BMI 20.0-24.9kg/m²)\n—\n—\n\n\n\n\n    Class I obesity (BMI 30.0-34.9kg/m²)\n0.54\n0.51, 0.57\n&lt;0.001\n\n\n    Class II obesity (BMI 35.0-39.9kg/m²)\n0.56\n0.53, 0.59\n&lt;0.001\n\n\n    Class III obesity (BMI ≥40.0kg/m²)\n0.78\n0.74, 0.82\n&lt;0.001\n\n\n    Overweight (BMI 25.0-29.9kg/m²)\n0.75\n0.70, 0.79\n&lt;0.001\n\n\n    Underweight (BMI ≤19.9kg/m²)\n1.38\n1.31, 1.45\n&lt;0.001\n\n\nAge, y\n1.03\n1.03, 1.03\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n1.13\n1.09, 1.16\n&lt;0.001\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n1.25\n1.13, 1.38\n&lt;0.001\n\n\n    Black\n0.97\n0.92, 1.01\n0.15\n\n\n    Hispanic\n1.08\n1.02, 1.15\n0.014\n\n\n    Native American\n1.18\n0.96, 1.45\n0.12\n\n\n    Other\n1.12\n1.02, 1.24\n0.017\n\n\nPrior CABG\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.92\n0.88, 0.95\n&lt;0.001\n\n\nPrior MI\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.76\n0.73, 0.79\n&lt;0.001\n\n\nPrior PCI\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.79\n0.76, 0.82\n&lt;0.001\n\n\nCharlson comorbidity index\n1.16\n1.15, 1.17\n&lt;0.001\n\n\nAtrial fibrillation\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.28\n1.24, 1.32\n&lt;0.001\n\n\nCerebrovascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.15\n1.10, 1.20\n&lt;0.001\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.38\n1.33, 1.42\n&lt;0.001\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.90\n0.86, 0.93\n&lt;0.001\n\n\nDementia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.08\n1.03, 1.13\n&lt;0.001\n\n\nTobbacco use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.91\n0.75, 1.10\n0.3\n\n\nCOPD\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.85\n0.83, 0.88\n&lt;0.001\n\n\nValvular heart disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.94\n0.91, 0.98\n0.002\n\n\nLiver disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2.39\n2.28, 2.50\n&lt;0.001\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.78\n0.75, 0.81\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.69\n0.66, 0.73\n&lt;0.001\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.86\n0.83, 0.90\n&lt;0.001\n\n\nDialysis dependence\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.44\n1.36, 1.53\n&lt;0.001\n\n\nAnemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.77\n0.73, 0.82\n&lt;0.001\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.69\n0.66, 0.71\n&lt;0.001\n\n\nCancer\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.02\n0.97, 1.08\n0.4\n\n\n\n1 OR = Odds Ratio, CI = Confidence Interval"
  },
  {
    "objectID": "quarto/index.html#multivariable-linear-regression",
    "href": "quarto/index.html#multivariable-linear-regression",
    "title": "Impact of Body Mass Index on Mortality in Hospitalized Patients With Coronary Artery Disease",
    "section": "Multivariable Linear Regression:",
    "text": "Multivariable Linear Regression:\n\nLength of Stay:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta\n95% CI1\np-value\n\n\n\n\nBody mass index (BMI)\n\n\n\n\n\n\n\n\n    Normal weight (BMI 20.0-24.9kg/m²)\n—\n—\n\n\n\n\n    Class I obesity (BMI 30.0-34.9kg/m²)\n-1.7\n-1.8, -1.6\n&lt;0.001\n\n\n    Class II obesity (BMI 35.0-39.9kg/m²)\n-1.8\n-1.9, -1.7\n&lt;0.001\n\n\n    Class III obesity (BMI ≥40.0kg/m²)\n-1.4\n-1.5, -1.3\n&lt;0.001\n\n\n    Overweight (BMI 25.0-29.9kg/m²)\n-0.81\n-0.89, -0.73\n&lt;0.001\n\n\n    Underweight (BMI ≤19.9kg/m²)\n-0.16\n-0.25, -0.07\n&lt;0.001\n\n\nAge, y\n-0.01\n-0.01, 0.00\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n0.10\n0.07, 0.13\n&lt;0.001\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n0.57\n0.40, 0.73\n&lt;0.001\n\n\n    Black\n0.42\n0.36, 0.48\n&lt;0.001\n\n\n    Hispanic\n0.24\n0.15, 0.32\n&lt;0.001\n\n\n    Native American\n-0.23\n-0.44, -0.03\n0.027\n\n\n    Other\n0.31\n0.16, 0.46\n&lt;0.001\n\n\nPrior CABG\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.56\n-0.60, -0.52\n&lt;0.001\n\n\nPrior MI\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.60\n-0.64, -0.56\n&lt;0.001\n\n\nPrior PCI\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.65\n-0.68, -0.62\n&lt;0.001\n\n\nCharlson comorbidity index\n0.26\n0.24, 0.27\n&lt;0.001\n\n\nAtrial fibrillation\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.67\n0.63, 0.71\n&lt;0.001\n\n\nCerebrovascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.80\n0.74, 0.87\n&lt;0.001\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.57\n0.53, 0.60\n&lt;0.001\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.03\n-0.08, 0.02\n0.2\n\n\nDementia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.52\n0.45, 0.60\n&lt;0.001\n\n\nTobbacco use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.37\n-0.51, -0.23\n&lt;0.001\n\n\nCOPD\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.20\n-0.23, -0.16\n&lt;0.001\n\n\nValvular heart disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.39\n0.34, 0.44\n&lt;0.001\n\n\nLiver disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.62\n0.54, 0.71\n&lt;0.001\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.06\n-0.10, -0.03\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.26\n-0.32, -0.20\n&lt;0.001\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.01\n-0.03, 0.06\n0.6\n\n\nDialysis dependence\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.18\n0.10, 0.26\n&lt;0.001\n\n\nAnemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.86\n0.79, 0.93\n&lt;0.001\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.56\n-0.60, -0.52\n&lt;0.001\n\n\nCancer\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.48\n0.41, 0.56\n&lt;0.001\n\n\n\n1 CI = Confidence Interval\n\n\n\n\n\n\n\n\n\n\nInflation Adjusted Total Charge:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta\n95% CI1\np-value\n\n\n\n\nBody mass index (BMI)\n\n\n\n\n\n\n\n\n    Normal weight (BMI 20.0-24.9kg/m²)\n—\n—\n\n\n\n\n    Class I obesity (BMI 30.0-34.9kg/m²)\n1,137\n-401, 2,675\n0.15\n\n\n    Class II obesity (BMI 35.0-39.9kg/m²)\n-2,980\n-4,514, -1,446\n&lt;0.001\n\n\n    Class III obesity (BMI ≥40.0kg/m²)\n-5,347\n-6,983, -3,711\n&lt;0.001\n\n\n    Overweight (BMI 25.0-29.9kg/m²)\n6,135\n4,555, 7,715\n&lt;0.001\n\n\n    Underweight (BMI ≤19.9kg/m²)\n-1,673\n-3,228, -118\n0.035\n\n\nAge, y\n-516\n-553, -478\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n8,599\n8,024, 9,174\n&lt;0.001\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n34,990\n30,054, 39,926\n&lt;0.001\n\n\n    Black\n-2,601\n-4,016, -1,185\n&lt;0.001\n\n\n    Hispanic\n24,877\n22,319, 27,435\n&lt;0.001\n\n\n    Native American\n-8,959\n-13,041, -4,877\n&lt;0.001\n\n\n    Other\n24,508\n19,403, 29,613\n&lt;0.001\n\n\nPrior CABG\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-18,115\n-18,935, -17,296\n&lt;0.001\n\n\nPrior MI\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-12,112\n-12,818, -11,405\n&lt;0.001\n\n\nPrior PCI\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-12,635\n-13,286, -11,984\n&lt;0.001\n\n\nCharlson comorbidity index\n2,795\n2,553, 3,036\n&lt;0.001\n\n\nAtrial fibrillation\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n8,735\n7,954, 9,517\n&lt;0.001\n\n\nCerebrovascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n10,430\n9,291, 11,570\n&lt;0.001\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n3,125\n2,418, 3,833\n&lt;0.001\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n3,813\n2,869, 4,757\n&lt;0.001\n\n\nDementia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-13,873\n-14,854, -12,891\n&lt;0.001\n\n\nTobbacco use disorder\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-3,699\n-6,647, -752\n0.014\n\n\nCOPD\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-10,484\n-11,193, -9,776\n&lt;0.001\n\n\nValvular heart disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n21,319\n20,054, 22,583\n&lt;0.001\n\n\nLiver disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n8,311\n6,659, 9,963\n&lt;0.001\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-3,788\n-4,455, -3,122\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-3,781\n-4,816, -2,746\n&lt;0.001\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-8,869\n-9,775, -7,963\n&lt;0.001\n\n\nDialysis dependence\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n5,623\n4,222, 7,024\n&lt;0.001\n\n\nAnemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n412\n-706, 1,531\n0.5\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n791\n-4.4, 1,586\n0.051\n\n\nCancer\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n4,016\n2,684, 5,349\n&lt;0.001\n\n\n\n1 CI = Confidence Interval"
  }
]